Andere Kunden interessierten sich auch für
![Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?]( "Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?")
Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?24,00 €![Traditionelles Wissen indigener und lokaler Gemeinschaften zwischen geistigen Eigentumsrechten und der]( "Traditionelles Wissen indigener und lokaler Gemeinschaften zwischen geistigen Eigentumsrechten und der")
Traditionelles Wissen indigener und lokaler Gemeinschaften zwischen geistigen Eigentumsrechten und der "public domain"84,95 €![Competition Law in Switzerland]( "Competition Law in Switzerland")
Competition Law in Switzerland66,99 €![Competition Law in Switzerland]( "Competition Law in Switzerland")
Competition Law in Switzerland48,99 €![European Merger Control]( "European Merger Control")
European Merger Control178,99 €![Report of Hearings On H.R. 23431 to Regulate the Practice of Osteopathy, to License Osteopathic Physicians, and to Punish Persons Violating the Provis]( "Report of Hearings On H.R. 23431 to Regulate the Practice of Osteopathy, to License Osteopathic Physicians, and to Punish Persons Violating the Provis")
Report of Hearings On H.R. 23431 to Regulate the Practice of Osteopathy, to License Osteopathic Physicians, and to Punish Persons Violating the Provis34,99 €![Contemporary Issues in Pharmaceutical Patent Law]( "Contemporary Issues in Pharmaceutical Patent Law")
Contemporary Issues in Pharmaceutical Patent Law211,99 €
FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.The author is Hirotaka Nonaka; an attorney-at-law and patent attorney in Tokyo, Japan, handling particularly IP-related disputes and consulting.